Media Summary: Moffitt's physician team includes cancer surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and more, ... Off-the-shelf CAR T could help offer this therapy to more people. Cellular immunotherapy is changing the way cancer patients are treated by using living immune

Doris Hansen Md And Fred Locke Md At Cell Coast Conference 2024 - Detailed Analysis & Overview

Moffitt's physician team includes cancer surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and more, ... Off-the-shelf CAR T could help offer this therapy to more people. Cellular immunotherapy is changing the way cancer patients are treated by using living immune At Moffitt Cancer Center, cutting-edge immunotherapy for cancer is transforming lives. In this inspiring video, meet a resilient ...

Photo Gallery

Doris Hansen, MD and Fred Locke, MD at Cell Coast Conference 2024
ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy
Frederick Locke, MD with Natasha Kekre, MD and Rizwan Romee, MD at Cell Coast Conference 2024
Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM
Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma
Dr. Doris Hansen at TANDEM 2023
ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma
Dr. Doris Hansen at TANDEM 2023: Abstract 256
Dr. Doris Hansen at ASCO 2022: Abstract No. 8042
ASCO 2024: Dr. Fred Locke Discusses Immunotherapy
Drs. Kedar Kirtane and Doris Hansen on Advances in Multiple Myeloma Treatment
Comparisons in Time to Next Treatment in Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma
Sponsored
Sponsored
View Detailed Profile
Doris Hansen, MD and Fred Locke, MD at Cell Coast Conference 2024

Doris Hansen, MD and Fred Locke, MD at Cell Coast Conference 2024

During #CellCoast24,

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

At ASH

Sponsored
Frederick Locke, MD with Natasha Kekre, MD and Rizwan Romee, MD at Cell Coast Conference 2024

Frederick Locke, MD with Natasha Kekre, MD and Rizwan Romee, MD at Cell Coast Conference 2024

At #CellCoast24,

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

At #ASH25,

Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

From #ASH25:

Sponsored
Dr. Doris Hansen at TANDEM 2023

Dr. Doris Hansen at TANDEM 2023

LIVE from TANDEM 2023:

ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma

ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma

Doris Hansen

Dr. Doris Hansen at TANDEM 2023: Abstract 256

Dr. Doris Hansen at TANDEM 2023: Abstract 256

LIVE from Orlando:

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr

ASCO 2024: Dr. Fred Locke Discusses Immunotherapy

ASCO 2024: Dr. Fred Locke Discusses Immunotherapy

Moffitt Cancer Center's

Drs. Kedar Kirtane and Doris Hansen on Advances in Multiple Myeloma Treatment

Drs. Kedar Kirtane and Doris Hansen on Advances in Multiple Myeloma Treatment

At #CellCoast25, Kedar Kirtane,

Comparisons in Time to Next Treatment in Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

Comparisons in Time to Next Treatment in Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

Interview with

Frederick Locke, MD-  Blood & Marrow Transplant and Cellular Immunotherapy

Frederick Locke, MD- Blood & Marrow Transplant and Cellular Immunotherapy

Moffitt's physician team includes cancer surgeons, medical oncologists, radiation oncologists, radiologists, pathologists and more, ...

Links to Early Responses in Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

Links to Early Responses in Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

Interview with

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

At ASCO 2023:

ASCO 2021 - Fred Locke, MD - Abstract 2529

ASCO 2021 - Fred Locke, MD - Abstract 2529

Off-the-shelf CAR T could help offer this therapy to more people.

Dr. Frederick Locke on the Latest in Cellular Immunotherapy

Dr. Frederick Locke on the Latest in Cellular Immunotherapy

Cellular immunotherapy is changing the way cancer patients are treated by using living immune

Immunotherapy Treatment for Cancer: The Inspiring Story of Dimas and Dr. Locke

Immunotherapy Treatment for Cancer: The Inspiring Story of Dimas and Dr. Locke

At Moffitt Cancer Center, cutting-edge immunotherapy for cancer is transforming lives. In this inspiring video, meet a resilient ...

Dr. Frederick Locke at ASCO 2022: Abstract No. 7565

Dr. Frederick Locke at ASCO 2022: Abstract No. 7565

Dr